HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Abstract Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (42) Citing Articles via Google Scholar Google Scholar Articles by Hurd, S. Search for Related Content PubMed PubMed Citation Articles by Hurd, S.

The Impact of COPD on Lung Health Worldwide^*

Epidemiology and Incidence

^* From the Division of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD.

Correspondence to: Suzanne Hurd, PhD, Division of Lung Diseases, National Heart, Lung, and Blood Institute, 6701 Rockledge Dr, Suite 10122, Bethesda, MD, 20892

	Abstract

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 
Information on the prevalence of COPD was obtained from vital statistics, health interview surveys, hospital charge records, national publications, and the World Health Organization (WHO). These data indicate that COPD is a common disease with implications for global health. In the United States, morbidity caused by COPD is 4%, making COPD the fourth leading cause of death, exceeded only by heart attacks, cancer, and stroke. Internationally, there is substantial variation in death rates possibly reflecting smoking behavior, type and processing of tobacco, pollution, climate, respiratory management, and genetic factors. The Global Obstructive Lung Disease Initiative, initiated by the National Heart, Lung, and Blood Institute and the WHO, aims to raise awareness of the increasing burden of COPD, decrease morbidity and mortality, promote further study of the condition, and implement programs to prevent COPD.

Key Words: COPD • education programs • morbidity • public health

	Introduction

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 
COPD is a common, costly, and preventable disease that has implications for global health. It is the fourth leading cause of death in the United States, exceeded only by heart attacks, cancers, and stroke (Table 1) .¹ Among 28 industrialized countries, the United States ranks 12th in COPD mortality for men and seventh for women. It has been estimated that by the year 2020, COPD will be fifth among the conditions that will be the highest burden to society on a worldwide scale.² Hospitalization rates are rising dramatically. Economic costs are enormous, estimated at > $14 billion in the United States. At best, current treatments, although very valuable in selected patients, are only palliative.

	Course of Disease

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 
In the mid-1980s, the National Heart, Lung, and Blood Institute (NHLBI) initiated a long-term, multicenter project, the Lung Health Study, to determine whether a program incorporating smoking intervention and the use of an inhaled bronchodilator can slow the rate of decline in FEV₁. The study followed nearly 6,000 male and female smokers aged 35 to 60 years with mild obstructive pulmonary disease. Major study results were reported in November 1994.³ An aggressive smoking intervention program significantly reduced the age-related decline in FEV₁ in middle-aged smokers with mild airways obstruction. Use of an inhaled anticholinergic bronchodilator resulted in relatively small improvements in FEV₁, which appeared to be reversed after the drug was discontinued. Use of the bronchodilator did not influence the long-term decline of FEV₁.

Since the publication of that major study outcome, much has been learned about the study population. For example, from data already analyzed, > 2% of the patients screened for the Lung Health Study developed lung cancer. Although success in smoking cessation can protect lung function in a group at high risk of developing a progressive decline in FEV₁ as a prelude to symptomatic COPD, a 5-year sustained smoking cessation rate was very hard to achieve despite the intensive interventions. This underscores the need to increase efforts at prevention of smoking. There is also a need to continue to explore approaches for early detection of disease, including pulmonary function measures, biochemical or immunologic tests, or identification of genetic markers of susceptible smokers.

	Magnitude of the Problem in the United States

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 
Prevalence
Data on the prevalence of COPD depend on multiple factors, such as diagnostic criteria, potential confounding conditions, the need to make appropriate age adjustments, and the requirement to make adjustments for revisions in the International Classification of Disease (ICD) codes. Thus, estimates of the frequency and distribution of COPD tend to be inadequate and incomplete. In the United States, estimates of prevalence have been developed from responses to standard questions asked of representative samples of the civilian noninstitutionalized population in the National Health Interview Surveys from the National Center for Health Statistics (Table 2) .¹ In 1994, there were estimated to be 14.021 million men and women with chronic bronchitis, 2.208 million with emphysema, and 14.562 million with asthma. Rates (unadjusted for age) of reporting emphysema were higher for men than women, whereas rates of reporting chronic bronchitis and asthma were higher for women than men. Table 2 also shows larger numbers of affected persons and higher rates of reporting of these conditions in 1994 than in 1986 and 1970 for both chronic bronchitis and asthma; rates of emphysema declined in 1994 compared with previous years in both men and women.

Hospitalizations
Between 1970 and 1995, in the United States, COPD hospitalization rates varied considerably, although the reasons for this variation are not clear. Hospital discharge data from the National Center for Health Statistics relate to numbers and rates of discharges for related conditions according to whether they are listed as first or as a subordinate cause of hospitalization. Unfortunately, discharges for individual patients admitted more than once in the course of the year cannot be linked. For the entire group of conditions, there were 553,000 discharges with COPD or allied conditions given as the first listed diagnosis; more than half of these were coded as bronchitis, chronic and unqualified, ICD codes 490 and 491.¹

Mortality
COPD accounted for 4% of all deaths in the United States in 1995, fourth highest among causes of death (Table 1) . The numbers of deaths attributed to COPD in 1985 and 1995 are shown in Table 3 , which provides information on the specific conditions entered on death certificates for COPD deaths. In 1995, the age-adjusted death rate per 100,000 population was 54.7 for white men, 42.5 for black men, 31.4 for white women, and 15.6 for black women. Although highest in white men, COPD mortality rates for white men have remained relatively constant since the 1980s. During the same period, the rate gradually increased in black men but doubled in white women and in black women.¹

	Time Trends in Morbidity and Mortality From COPD in the United States

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

	International Comparisons of COPD Mortality and Morbidity

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 
Death rates for COPD and allied conditions for men and women aged 35 to 74 years are shown by country for the latest year available from the WHO (Fig 1) . Among 28 industrialized countries, the United States ranks 12th in COPD mortality for men and seventh for women. Taken at face value, these data indicate substantial variation among countries for both sexes. Death rates were lower among women than among men in every nation. Differences in COPD death rates among countries have attracted considerable attention, with multiple hypotheses suggested including smoking behaviors, type and processing of tobacco used in cigarettes, outdoor and indoor pollution, climate, frequency and management of respiratory infections, and genetic factors. However, the lack of standardization of death certification and coding practices as well as differences in diagnostic practices and availability and quality of medical care in different countries severely curtails the interpretation of the data.

View larger version (30K): [in this window] [in a new window] [Download PPT slide]   Figure 1.. Age-adjusted death rates for COPD by country and by sex, ages 35 to 74 years (adapted from World Health Statistics Annual, WHO, unpublished).

	Global Obstructive Lung Disease Initiative: International Program on COPD

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

	Summary

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 
COPD is the only leading cause of death that is increasing in prevalence. Although it is known that cigarette smoking is the major cause of this disease and, therefore, that COPD largely is preventable, COPD is already a major burden on the health-care community, a burden that will continue to escalate around the world in the next century. Work is under way, through an NHLBI/WHO Global Obstructive Lung Disease Initiative, to bring information about COPD to public health officials, the medical community, and the public. However, more effective methods are required for early detection of disease.

	Footnotes

 
Abbreviations: ICD = International Classification of Disease; NHLBI = National Heart, Lung, and Blood Institute; WHO = World Health Organization

	References

TOP Abstract Introduction Course of Disease Magnitude of the Problem... Time Trends in Morbidity... International Comparisons of... Global Obstructive Lung Disease... Summary References

 

1. NHLBI morbidity and mortality chartbook, 1998. Available at http://www.nhlbi.nih.gov/resources/docs/cht-book.htm
2. Murray, CJL, Lopez, AD (1996) Evidence-based health policy: lessons from the global burden of disease study. Science 274,740-743[Free Full Text]
3. Anthonisen, NR, Connett, JE, Kiley, JP, et al (1994) The Lung Health Study Research Group: effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV₁. JAMA 272,1497-1505[Abstract]

This article has been cited by other articles:

				S. Christensen, R. W. Thomsen, M. L. Torring, A. Riis, M. Norgaard, and H. T. Sorensen Impact of COPD on Outcome Among Patients With Complicated Peptic Ulcer Chest, June 1, 2008; 133(6): 1360 - 1366. [Abstract] [Full Text] [PDF]

				N. K. Leidy Evolving Concepts in the Measurement of Treatment Effects Proceedings of the ATS, May 1, 2006; 3(3): 212 - 217. [Abstract] [Full Text] [PDF]

				A. D. Lopez, K. Shibuya, C. Rao, C. D. Mathers, A. L. Hansell, L. S. Held, V. Schmid, and S. Buist Chronic obstructive pulmonary disease: current burden and future projections Eur. Respir. J., February 1, 2006; 27(2): 397 - 412. [Full Text] [PDF]

				R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]

				H. Kim, X. Liu, T. Kobayashi, H. Conner, T. Kohyama, F.-Q. Wen, Q. Fang, S. Abe, P. Bitterman, and S. I. Rennard Reversible Cigarette Smoke Extract-Induced DNA Damage in Human Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 483 - 490. [Abstract] [Full Text] [PDF]

				S. Suissa Inhaled steroids and mortality in COPD: bias from unaccounted immortal time Eur. Respir. J., March 1, 2004; 23(3): 391 - 395. [Abstract] [Full Text] [PDF]

				A.L. Hansell, J.A. Walk, and J.B. Soriano What do chronic obstructive pulmonary disease patients die from? Amultiple cause coding analysis Eur. Respir. J., November 1, 2003; 22(5): 809 - 814. [Abstract] [Full Text] [PDF]

				A. Malhotra, A. P. Peiffer, D. T. Ryujin, T. Elsner, R. E. Kanner, M. F. Leppert, and S. J. Hasstedt Further Evidence for the Role of Genes on Chromosome 2 and Chromosome 5 in the Inheritance of Pulmonary Function Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 556 - 561. [Abstract] [Full Text] [PDF]

				K. H. Groenewegen, A. M.W.J. Schols, and E. F.M. Wouters Mortality and Mortality-Related Factors After Hospitalization for Acute Exacerbation of COPD Chest, August 1, 2003; 124(2): 459 - 467. [Abstract] [Full Text] [PDF]

				S. Suissa Effectiveness of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Immortal Time Bias in Observational Studies Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 49 - 53. [Abstract] [Full Text] [PDF]

				P. E. Epstein Inhaled Corticosteroids and Chronic Obstructive Pulmonary Disease: Are We Barking Up the Wrong Tracheobronchial Tree? Ann Intern Med, June 17, 2003; 138(12): 1001 - 1002. [Full Text] [PDF]

				P. Buch, J. Friberg, H. Scharling, P. Lange, and E. Prescott Reduced lung function and risk of atrial fibrillation in The Copenhagen City Heart Study Eur. Respir. J., June 1, 2003; 21(6): 1012 - 1016. [Abstract] [Full Text] [PDF]

				C. Shin, K. H. In, J. J. Shim, S. H. Yoo, K. H. Kang, M. Hong, and K. Choi Prevalence and Correlates of Airway Obstruction in a Community-Based Sample of Adults Chest, June 1, 2003; 123(6): 1924 - 1931. [Abstract] [Full Text] [PDF]

				S.D. Sullivan, A.S. Buist, and K. Weiss Health outcomes assessment and economic evaluation in COPD: challenges and opportunities Eur. Respir. J., June 1, 2003; 21(41_suppl): 1S - 3s. [Full Text] [PDF]

				J. Bourbeau Inhaled corticosteroids and survival in chronic obstructive pulmonary disease Eur. Respir. J., February 1, 2003; 21(2): 202 - 203. [Full Text] [PDF]

				D.D. Sin and S.F.P. Man Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur. Respir. J., February 1, 2003; 21(2): 260 - 266. [Abstract] [Full Text] [PDF]

				S. Rennard, M. Decramer, P.M.A. Calverley, N.B. Pride, J.B. Soriano, P.A. Vermeire, and J. Vestbo Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey Eur. Respir. J., October 1, 2002; 20(4): 799 - 805. [Abstract] [Full Text] [PDF]

				R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, and G.W. Sybrecht Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Eur. Respir. J., May 1, 2002; 19(5): 936 - 943. [Abstract] [Full Text] [PDF]

				P. Almagro, E. Calbo, A. Ochoa de Echaguen, B. Barreiro, S. Quintana, J. L. Heredia, and J. Garau Mortality After Hospitalization for COPD* Chest, May 1, 2002; 121(5): 1441 - 1448. [Abstract] [Full Text] [PDF]

				D. D. SIN and J. V. TU Inhaled Corticosteroids and the Risk of Mortality and Readmission In Elderly Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 580 - 584. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (42) Citing Articles via Google Scholar Google Scholar Articles by Hurd, S. Search for Related Content PubMed PubMed Citation Articles by Hurd, S.